



Napier House 24 High Holborn London WC1V 6AZ email: COVID-19@icnarc.org

www.icnarc.org

ICNARC report on COVID-19 in critical care 17 July 2020

This report presents analyses of data on patients critically ill with confirmed COVID-19 reported to ICNARC up to 4pm on 16 July 2020 from critical care units participating in the Case Mix Programme (the national clinical audit covering all NHS adult, general intensive care and combined intensive care/high dependency units in England, Wales and Northern Ireland, plus some additional specialist and non-NHS critical care units). Please note that adult critical care units in Scotland, paediatric intensive care units and neonatal intensive care units do not participate in the Case Mix Programme.

Reporting process

Critical care units participating in the Case Mix Programme are asked to:

- notify ICNARC as soon as they have an admission with confirmed COVID-19;
- submit early data for admissions with confirmed COVID-19, including demographics and first 24-hour physiology, as soon as possible after the end of the first 24 hours in critical care:
- resubmit data for the whole critical care stay, including critical care outcome and organ support, when the patient leaves critical care; and
- submit final data when the patient leaves acute hospital.

The same data are reported for an historic cohort of patients critically ill with viral pneumonia (non-COVID-19) admitted between 1 January 2017 and 31 December 2019.

Contents

Participation and population coverage	4
Patient characteristics	8
Patient characteristics by ethnicity	12
Patient characteristics by receipt of organ support	14
Outcomes, duration of critical care and organ support	18
Outcomes by patient characteristics	23
Outcomes by receipt of organ support	25
Patient characteristics and outcomes for longer stay patients	31
Multivariable analyses	34
Data completeness	38
Definitions	39
Acknowledgement	40

List of tables

Table 1	Patient characteristics: demographics	8
Table 2	Patient characteristics: medical history and indicators of acute severity *	9
Table 3	Patient characteristics: demographics by ethnicity *	12
Table 4	Patient characteristics: medical history and indicators of acute severity by	
	ethnicity *	13
Table 5	Patient characteristics: demographics by receipt of respiratory support *	14
Table 6	Patient characteristics: medical history and indicators of acute severity by re	ceipt
	of respiratory support *	15
Table 7	Patient characteristics: demographics by receipt of renal support *	16
Table 8	Patient characteristics: medical history and indicators of acute severity by re	ceipt
	of renal support *	17
Table 9	Outcome, duration of critical care and organ support *	20
Table 10	Outcome by patient characteristics	23
Table 11	Outcome, duration of critical care and organ support by ethnicity *	24
Table 12	Outcome by combinations of organ support *	26
Table 13	Outcome, duration of critical care and organ support by receipt of respiratory	/
	support *	27
Table 14	Outcome, duration of critical care and organ support by receipt of renal supp	ort *
		28
Table 15	Outcome by receipt of respiratory support * and patient characteristics	29
Table 16	Outcome by receipt of renal support * and patient characteristics	30
Table 17	Patient characteristics: demographics for patients receiving critical care for a	l
	total of 28 days or more	31
Table 18	Patient characteristics: medical history and indicators of acute severity for	
	patients receiving critical care for a total of 28 days or more	32
Table 19	Outcome, duration of critical care and organ support for patients receiving cr	itical
	care for a total of 28 days or more	33
Table 20	Data completeness of key variables	38

List of figures

Figure 1	Numbers of patients with data included in this report and outstanding *	. 4
Figure 2	New patients included this week by week of start critical care	. 5
Figure 3	New patients with a start of critical care in the last two weeks by region	. 5
Figure 4	Number of new patients critically ill with confirmed COVID-19 by date of start of	:
	critical care	. 6
Figure 5	Cumulative number of patients critically ill with confirmed COVID-19 by date of	
	start of critical care	. 6
Figure 6	Total number of patients critically ill with confirmed COVID-19 by date *	. 7
Figure 7	Number of admissions critically ill with confirmed COVID-19 by Critical Care	
	Network *	. 7
Figure 8	Age and sex distribution of patients critically ill with confirmed COVID-19	10
Figure 9	Ethnicity distribution of patients critically ill with confirmed COVID-19	10
Figure 10	Index of Multiple Deprivation (IMD) * distribution of patients critically ill with	
	confirmed COVID-19	11
Figure 11	BMI distribution of patients critically ill with confirmed COVID-19	11
Figure 12	Critical care and acute hospital outcomes among patients with at least 24h data	ì
	received	18
Figure 13	Cumulative outcomes by date of start of critical care *	19
Figure 14	Survival and discharge among patients with at least 24h data received	19
Figure 15	Percentage of patients receiving organ support *	21
Figure 16	Duration of organ support received *	21
Figure 17	Median lengths of stay among patients with hospital outcome data received	22
Figure 18	Inter-hospital critical care transfers and readmissions	22
Figure 19	Survival and discharge by mechanical ventilation during the first 24 hours *	25
Figure 20	Hazard ratios and 95% confidence intervals from Cox proportional hazards	
	regression model for death within 30 days following start of critical care:	
	demographics and medical history	35
Figure 21	Hazard ratios and 95% confidence intervals from Cox proportional hazards	
	regression model for death within 30 days following start of critical care:	
	physiology (1)	36
Figure 22		
-	regression model for death within 30 days following start of critical care:	
	physiology (2)	37

^{*} Please see individual notes for Tables/Figures

Critical care unit participation

Total number of units: 289
Units with at least one patient notified: 258
Units with zero patients: 29
Units with uncertain participation: 2

Admissions to critical care

To date, ICNARC have been notified of 13,268 admissions for critical care with confirmed COVID-19, either at or after the start of critical care, in England, Wales and Northern Ireland. Of these, early data covering the first 24 hours of critical care have been submitted to ICNARC for 12,904 admissions for 10,492 patients (Figure 1). Of the 10,492 patients, 10,118 have outcomes reported and 374 patients were last reported as still receiving critical care.

Of the 71 new patients included in the report for the first time this week, 18 were admitted to critical care within the last week (Figure 2), with the majority representing back-filling of cases from the peak of the epidemic. Of 66 patients with a start of critical care in the last two weeks (02/07/2020 to 15/07/2020), the largest numbers were admitted in the North East And Yorkshire, North West and East Of England regions (Figure 3).




Figure 1 Numbers of patients with data included in this report and outstanding *

^{*} Please note that 24-hour data are considered outstanding where ICNARC was notified of the admission at least 48 hours previously and outcome data are considered outstanding when 24-hour data have been received and at least 10 days have elapsed since the start of critical care.




Figure 2 New patients included this week by week of start critical care




Figure 3 New patients with a start of critical care in the last two weeks by region

The numbers of new patients, cumulative numbers of patients and number of patients in critical care by date are shown in Figures 4-6. The largest numbers of patients (2992) have been managed by the three London Operational Delivery Networks (Figure 7). Please note that Figures 4-6 are affected by a variable lag time for submission of data (shaded grey).




Figure 4 Number of new patients critically ill with confirmed COVID-19 by date of start of critical care




Figure 5 Cumulative number of patients critically ill with confirmed COVID-19 by date of start of critical care




Figure 6 Total number of patients critically ill with confirmed COVID-19 by date *

^{*} Please note that patients whose outcome data have not been received are assumed to remain in critical care as of 16 July 2020.



Figure 7 Number of admissions critically ill with confirmed COVID-19 by Critical Care Network *

ODN: Organisational Delivery Network; CCN: Critical Care Network. * Please note that this figure represents the number of admissions (i.e. includes transfers between units and readmissions) and NOT the number of patients.

Characteristics of patients critically ill with confirmed COVID-19 are summarised in Table 1 and Table 2 and compared with an historic cohort of patients critically ill with viral pneumonia (non-COVID-19) admitted between 1 January 2017 and 31 December 2019.

Table 1 Patient characteristics: demographics

Demographics	Patients with confirmed COVID-19 and 24h data (N=10492)	Patients with viral pneumonia (non-COVID-19), 2017-19 (N=5782)
Age at admission (years) [N=10481]		
Mean (SD)	58.8 (12.7)	58.0 (17.4)
Median (IQR)	60 (51, 68)	61 (48, 71)
Sex, n (%) [N=10485]		
Female	3117 (29.7)	2641 (45.7)
Male	7368 (70.3)	3141 (54.3)
Currently or recently pregnant, n (% of females aged	16-49) [N=744]	
Currently pregnant	28 (3.8)	56 (7.4)
Recently pregnant (within 6 weeks)	39 (5.2)	29 (3.8)
Not known to be pregnant	677 (91.0)	674 (88.8)
Ethnicity *, n (%) [N=10075]		
White	6655 (66.1)	4951 (88.4)
Mixed	185 (1.8)	52 (0.9)
Asian	1574 (15.6)	325 (5.8)
Black	978 (9.7)	155 (2.8)
Other	683 (6.8)	117 (2.1)
Index of Multiple Deprivation (IMD) quintile *, n (%) [N	\= 9771]	
1 (least deprived)	1403 (14.4)	873 (15.3)
2	1566 (16.0)	999 (17.5)
3	1918 (19.6)	1115 (19.5)
4	2357 (24.1)	1232 (21.6)
5 (most deprived)	2527 (25.9)	1489 (26.1)
Body mass index *, n (%) [N=9918]		
<18.5	76 (0.8)	310 (5.5)
18.5-<25	2532 (25.5)	1933 (34.2)
25-<30	3423 (34.5)	1691 (29.9)
30-<40	3107 (31.3)	1330 (23.5)
40+	780 (7.9)	394 (7.0)

^{*} Please see Definitions on page 39.

Table 2 Patient characteristics: medical history and indicators of acute severity *

Dependency prior to admission to acute hospital *, n (%) [N=10317] Able to live without assistance in daily activities 9261 (89.8) 4244 (73.6) Some assistance with daily activities 39 (0.4) 1392 (24.1) Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] Cardiovascular 71 (0.7) 78 (1.4) Respiratory 126 (1.2) 295 (5.1) Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0.3) 1 (0.2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736]	Medical history	Patients with confirmed COVID-19 and 24h data (N=10492)	Patients with viral pneumonia (non-COVID-19), 2017-19 (N=5782)
Some assistance with daily activities 1017 (9.9) 1392 (24.1) Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] Total comorbidities *, n (%) [N=1040] 126 (1.2) 295 (5.1) Rean (SD) 46 (0.4) 54 (0.9) 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) 46 (0.4) 54 (0.9) Metamtological malignancy 200 (1.9) 268 (4.6) 18 (1.2) Immunocompromise 368 (3.6) 503 (8.7) 7 Prior hospital length of stay [N=10486] 2.5 (6.3) 2.7 (13.0) 2.7 (13.0) Median (IQR) 1 (0.3) 1 (0.2) 21 (0.4) 1.5 In the community 55 (0.5) 21 (0.4) 21 (0.4) 1.5 Indicator of acute severity 6020 (59.1)	Dependency prior to admission to acute hospital *, r	n (%) [N=10317]	
Total assistance with all daily activities 39 (0.4) 134 (2.3) Very severe comorbidities *, n (%) [N=10357] 71 (0.7) 78 (1.4) Cardiovascular 71 (0.7) 78 (1.4) Respiratory 126 (1.2) 295 (5.1) Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] 2.5 (6.3) 2.7 (13.0) Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] 1 1 In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 50 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18)	Able to live without assistance in daily activities	9261 (89.8)	4244 (73.6)
Very severe comorbidities *, n (%) [N=10357] Cardiovascular 71 (0.7) 78 (1.4) Respiratory 126 (1.2) 295 (5.1) Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] 2.5 (6.3) 2.7 (13.0) Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 6020 (59.1) 2482 (43.0) Median (IQR) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)	Some assistance with daily activities	1017 (9.9)	1392 (24.1)
Cardiovascular Respiratory Respiratory 126 (1.2) 295 (5.1) Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) Prior hospital length of stay [N=10486] Mean (SD) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community In hospital Nechanically ventilated within first 24h *, n (%) [N=10186] APACHE II Score [N=10312] Mean (SD) Median (IQR) 1 (10, 7) 1 (10, 18) 1 (10, 1		39 (0.4)	134 (2.3)
Respiratory 126 (1.2) 295 (5.1) Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] 1 1 In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 6020 (59.1) 2482 (43.0) Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)			
Renal 179 (1.7) 120 (2.1) Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10486] APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	Cardiovascular	71 (0.7)	78 (1.4)
Liver 46 (0.4) 54 (0.9) Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10486] APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	Respiratory	126 (1.2)	295 (5.1)
Metastatic disease 60 (0.6) 68 (1.2) Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] 2.5 (6.3) 2.7 (13.0) Mean (SD) 1 (0,3) 1 (0,2) CPR within previous 24h, n (%) [N=10470] 1 (0,4) 1 (0,2) In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 6020 (59.1) 2482 (43.0) Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)	Renal	179 (1.7)	120 (2.1)
Haematological malignancy 200 (1.9) 268 (4.6) Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486] Mean (SD)	Liver	46 (0.4)	54 (0.9)
Immunocompromise 368 (3.6) 503 (8.7) Prior hospital length of stay [N=10486]	Metastatic disease	60 (0.6)	68 (1.2)
Prior hospital length of stay [N=10486] Mean (SD) Median (IQR) CPR within previous 24h, n (%) [N=10470] In the community In hospital In hospital In hospital In the community In the community In hospital In the community In hospital In the community In hospital In the community In the community In the community In hospital In the	Haematological malignancy	200 (1.9)	268 (4.6)
Mean (SD) 2.5 (6.3) 2.7 (13.0) Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) 6020 (59.1) 2482 (43.0) IN=10186] 482 (43.0) 482 (43.0) APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)	Immunocompromise	368 (3.6)	503 (8.7)
Median (IQR) 1 (0, 3) 1 (0, 2) CPR within previous 24h, n (%) [N=10470] In the community 55 (0.5) 21 (0.4) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)	Prior hospital length of stay [N=10486]	·	<u> </u>
CPR within previous 24h, n (%) [N=10470] In the community In hospital In hospi	Mean (SD)	2.5 (6.3)	2.7 (13.0)
In the community 55 (0.5) 21 (0.4) 73 (0.7) 85 (1.5) In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312]	Median (IQR)	1 (0, 3)	1 (0, 2)
In hospital 73 (0.7) 85 (1.5) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	CPR within previous 24h, n (%) [N=10470]		
Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 15.0 (5.3) 17.2 (6.3) Mean (SD) 15 (11, 18) 17 (13, 21) Median (IQR) 15 (11, 18) 17 (13, 21) PaO2/FiO2 ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO2/FiO2 ratio †, n (%) [N=9736]	In the community	55 (0.5)	21 (0.4)
Mechanically ventilated within first 24h *, n (%) 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] 15.0 (5.3) 17.2 (6.3) Median (SD) 15 (11, 18) 17 (13, 21) PaO2/FiO2 ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO2/FiO2 ratio †, n (%) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4)	In hospital	73 (0.7)	85 (1.5)
[N=10186] 6020 (59.1) 2482 (43.0) APACHE II Score [N=10312] Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	Indicator of acute severity		
Mean (SD) 15.0 (5.3) 17.2 (6.3) Median (IQR) 15 (11, 18) 17 (13, 21) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	•	6020 (59.1)	2482 (43.0)
Median (IQR) 15 (11, 18) 17 (13, 21) PaO2/FiO2 ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO2/FiO2 ratio †, n (%) [N=9736]	APACHE II Score [N=10312]		
PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736] 15.8 (11.2, 22.1) 18.0 (11.6, 26.4) PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	Mean (SD)	15.0 (5.3)	17.2 (6.3)
PaO ₂ /FiO ₂ ratio †, n (%) [N=9736]	Median (IQR)	15 (11, 18)	17 (13, 21)
	PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9736]	15.8 (11.2, 22.1)	18.0 (11.6, 26.4)
≤ 13.3 kPa (≤ 100 mmHg) 3591 (36.9) 1819 (33.3)	≤ 13.3 kPa (≤ 100 mmHg)	3591 (36.9)	1819 (33.3)
> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 4663 (47.9) 2318 (42.4)	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	· ·	· · ·
> 26.7 kPa (> 200 mmHg) 1482 (15.2) 1328 (24.3)	,	` ,	` '

^{*} Please see Definitions on page 39. Indicators of acute severity are based on data from the first 24 hours of critical care. † Derived from the arterial blood gas with the lowest PaO₂ during the first 24 hours of critical care.

The distribution of age and sex is presented in Figure 8. The distribution of ethnicity, matched on 2011 census ward for location of patients critically ill with COVID-19, is presented in Figure 9.




Figure 8 Age and sex distribution of patients critically ill with confirmed COVID-19




Figure 9 Ethnicity distribution of patients critically ill with confirmed COVID-19

The distribution of Index of Multiple Deprivation (IMD) is presented in Figure 10. The distribution of body mass index (BMI), compared with an age- and sex-matched population (from the Health Survey for England 2018), is presented in Figure 11.




Figure 10 Index of Multiple Deprivation (IMD) * distribution of patients critically ill with confirmed COVID-19

^{*} Please see Definitions on page 39.




Figure 11 BMI distribution of patients critically ill with confirmed COVID-19

Characteristics of patients critically ill with confirmed COVID-19 by ethnicity, for patients of white ethnicities compared with patients of all non-white ethnicities combined (mixed, Asian, black or other), are summarised in Table 3 and Table 4.

Table 3 Patient characteristics: demographics by ethnicity *

Demographics	Patients of white ethnicity (N=6655)	Patients of non-white ethnicity (N=3420)
Age at admission (years) [N=10064]		
Mean (SD)	60.6 (12.4)	55.4 (12.4)
Median (IQR)	62 (53, 70)	57 (47, 64)
Sex, n (%) [N=10068]		
Female	1999 (30.0)	1004 (29.4)
Male	4654 (70.0)	2411 (70.6)
Currently or recently pregnant, n (% of females) [N=72	0]	
Currently pregnant	12 (2.9)	15 (4.8)
Recently pregnant (within 6 weeks)	13 (3.2)	25 (8.0)
Not known to be pregnant	384 (93.9)	271 (87.1)
Index of Multiple Deprivation (IMD) quintile *, n (%) [N=	:9417]	
1 (least deprived)	1102 (17.7)	247 (7.7)
2	1144 (18.4)	364 (11.4)
3	1263 (20.3)	578 (18.1)
4	1296 (20.8)	966 (30.2)
5 (most deprived)	1413 (22.7)	1044 (32.6)
Body mass index *, n (%) [N=9532]		
<18.5	51 (0.8)	23 (0.7)
18.5-<25	1436 (22.9)	976 (29.9)
25-<30	2120 (33.8)	1179 (36.1)
30-<40	2089 (33.3)	905 (27.7)
40+	574 (9.2)	179 (5.5)

^{*} Please see Definitions on page 39. Patients with ethnicity recorded as 'not stated' excluded.

Table 4 Patient characteristics: medical history and indicators of acute severity by ethnicity *

Medical history	Patients of white ethnicity (N=6655)	Patients of non-white ethnicity (N=3420)
Dependency prior to admission to acute hospital *, n	, , -	
Able to live without assistance in daily activities	5787 (88.2)	3123 (93.0)
Some assistance with daily activities	747 (11.4)	224 (6.7)
Total assistance with all daily activities	26 (0.4)	12 (0.4)
Very severe comorbidities *, n (%) [N=9954]		
Cardiovascular	59 (0.9)	10 (0.3)
Respiratory	96 (1.5)	24 (0.7)
Renal	80 (1.2)	95 (2.8)
Liver	34 (0.5)	9 (0.3)
Metastatic disease	50 (0.8)	8 (0.2)
Haematological malignancy	152 (2.3)	36 (1.1)
Immunocompromise	266 (4.0)	82 (2.4)
Prior hospital length of stay [N=10071]		
Mean (SD)	2.6 (6.2)	2.2 (6.5)
Median (IQR)	1 (0, 3)	1 (0, 3)
CPR within previous 24h, n (%) [N=10057]	, ,	, ,
In the community	35 (0.5)	16 (0.2)
In hospital	40 (0.6)	26 (0.4)
Indicator of acute severity		
Mechanically ventilated within first 24h *, n (%) [N=9792]	3571 (55.0)	2203 (66.7)
APACHE II Score [N=9910]		
Mean (SD)	15.1 (5.2)	14.9 (5.4)
Median (IQR)	15 (12, 18)	14 (11, 18)
PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9359]	16.0 (11.3, 22.3)	15.4 (11.3, 21.7)
PaO ₂ /FiO ₂ ratio †, n (%) [N=9359]		
≤ 13.3 kPa (≤ 100 mmHg)	2249 (36.5)	1186 (37.1)
> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg)	2952 (47.9)	1556 (48.6)
> 26.7 kPa (> 200 mmHg)	959 (15.6)	457 (14.3)

^{*} Please see Definitions on page 39. Patients with ethnicity recorded as 'not stated' excluded. Indicators of acute severity are based on data from the first 24 hours of critical care. † Derived from the arterial blood gas with the lowest PaO₂ from the first 24 hours of critical care.

Characteristics of patients critically ill with confirmed COVID-19 who received advanced respiratory support at any point during critical care and those who received basic respiratory support only are summarised in Table 5 and Table 6. Characteristics of patients critically ill with confirmed COVID-19 who received renal support at any point during critical care and those who did not receive renal support are summarised in Table 7 and Table 8. Most patients who received renal support (95.0%) also received advanced respiratory support.

Table 5 Patient characteristics: demographics by receipt of respiratory support *

Demographics	Patients receiving advanced respiratory support (N=7277)	Patients receiving only basic respiratory support (N=2556)
Age at admission (years) [N=9824]		
Mean (SD)	58.7 (12.0)	59.4 (14.3)
Median (IQR)	60 (51, 67)	60 (50, 70)
Sex, n (%) [N=9826]		
Female	2026 (27.9)	853 (33.4)
Male	5245 (72.1)	1702 (66.6)
Currently or recently pregnant, n (% of females aged	16-49) [N=685]	
Currently pregnant	14 (3.0)	10 (4.6)
Recently pregnant (within 6 weeks)	26 (5.5)	9 (4.2)
Not known to be pregnant	429 (91.5)	197 (91.2)
Ethnicity *, n (%) [N=9462]		
White	4397 (62.9)	1863 (75.4)
Mixed	138 (2.0)	36 (1.5)
Asian	1155 (16.5)	303 (12.3)
Black	772 (11.0)	156 (6.3)
Other	529 (7.6)	113 (4.6)
Index of Multiple Deprivation (IMD) quintile *, n (%) [N	l =9152]	
1 (least deprived)	909 (13.5)	408 (16.8)
2	1049 (15.6)	422 (17.4)
3	1356 (20.2)	439 (18.1)
4	1687 (25.1)	527 (21.7)
5 (most deprived)	1722 (25.6)	633 (26.1)
Body mass index *, n (%) [N=9305]		
<18.5	38 (0.5)	26 (1.1)
18.5-<25	1717 (24.5)	604 (26.1)
25-<30	2456 (35.1)	790 (34.2)
30-<40	2263 (32.4)	669 (28.9)
40+	520 (7.4)	222 (9.6)

^{*} Please see Definitions on page 39. Patients receiving no respiratory support excluded due to small numbers.

Table 6 Patient characteristics: medical history and indicators of acute severity by receipt of respiratory support *

Medical history	Patients receiving advanced respiratory support (N=7277)	Patients receiving only basic respiratory support (N=2556)
Dependency prior to admission to acute hospital *, n	(%) [N=9704]	
Able to live without assistance in daily activities	6624 (92.2)	2106 (83.6)
Some assistance with daily activities	549 (7.6)	391 (15.5)
Total assistance with all daily activities	11 (0.2)	23 (0.9)
Very severe comorbidities *, n (%) [N=9727]		
Cardiovascular	21 (0.3)	45 (1.8)
Respiratory	42 (0.6)	76 (3.0)
Renal	89 (1.2)	70 (2.8)
Liver	24 (0.3)	18 (0.7)
Metastatic disease	23 (0.3)	26 (1.0)
Haematological malignancy	115 (1.6)	72 (2.8)
Immunocompromise	216 (3.0)	128 (5.1)
Prior hospital length of stay [N=9832]		
Mean (SD)	2.2 (5.4)	2.9 (7.1)
Median (IQR)	1 (0, 3)	1 (0, 3)
CPR within previous 24h, n (%) [N=9823]		_
In the community	45 (0.4)	6 (0.2)
In hospital	66 (0.6)	3 (0.1)
Indicator of acute severity		
Mechanically ventilated within first 24h *, n (%) [N=9630]	5676 (79.6)	
APACHE II Score [N=9712]		
Mean (SD)	15.4 (5.1)	14.2 (5.5)
Median (IQR)	15 (12, 18)	14 (10, 17)
PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9239]	15.2 (10.9, 21.1)	17.6 (12.7, 24.0)
PaO ₂ /FiO ₂ ratio †, n(%) [N=9239]		
≤ 13.3 kPa (≤ 100 mmHg)	2821 (40.0)	622 (28.5)
> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg)	3330 (47.2)	1159 (53.1)
> 26.7 kPa (> 200 mmHg)	904 (12.8)	403 (18.5)
, , ,	` '	

^{*} Please see Definitions on page 39. Patients receiving no respiratory support excluded due to small numbers. Indicators of acute severity are based on data from the first 24 hours of critical care. \dagger Derived from the arterial blood gas with the lowest PaO₂ from the first 24 hours of critical care.

Table 7 Patient characteristics: demographics by receipt of renal support *

Demographics	Patients receiving any renal support (N=2673)	Patients not receiving any renal support (N=7383)
Age at admission (years) [N=10047]		
Mean (SD)	59.1 (11.0)	58.8 (13.2)
Median (IQR)	60 (52, 67)	60 (51, 68)
Sex, n (%) [N=10049]		
Female	604 (22.6)	2369 (32.1)
Male	2067 (77.4)	5009 (67.9)
Currently or recently pregnant, n (% of females aged	16-49) [N=703]	_
Currently pregnant	2 (1.4)	24 (4.3)
Recently pregnant (within 6 weeks)	4 (2.9)	35 (6.2)
Not known to be pregnant	133 (95.7)	505 (89.5)
Ethnicity *, n (%) [N=9668]		
White	1511 (58.9)	4893 (68.9)
Mixed	44 (1.7)	131 (1.8)
Asian	428 (16.7)	1062 (14.9)
Black	394 (15.4)	552 (7.8)
Other	187 (7.3)	466 (6.6)
Index of Multiple Deprivation (IMD) quintile *, n (%) [I	N=9356]	
1 (least deprived)	319 (12.8)	1031 (15.0)
2	367 (14.8)	1132 (16.5)
3	527 (21.2)	1301 (18.9)
4	624 (25.1)	1645 (24.0)
5 (most deprived)	651 (26.2)	1759 (25.6)
Body mass index *, n (%) [N=9519]		
<18.5	13 (0.5)	58 (0.8)
18.5-<25	582 (22.5)	1818 (26.2)
25-<30	890 (34.3)	2416 (34.9)
30-<40	903 (34.8)	2084 (30.1)
40+	204 (7.9)	551 (8.0)

^{*} Please see Definitions on page 39. Includes 175 patients requiring chronic renal replacement therapy for end stage renal disease prior to critical care; outcomes for these patients are similar.

Table 8 Patient characteristics: medical history and indicators of acute severity by receipt of renal support *

Medical history	Patients receiving any renal support (N=2673)	Patients not receiving any renal support (N=7383)
Dependency prior to admission to acute hospital *, n	(%) [N=9924]	
Able to live without assistance in daily activities	2443 (92.2)	6457 (88.8)
Some assistance with daily activities	200 (7.6)	785 (10.8)
Total assistance with all daily activities	6 (0.2)	33 (0.5)
Very severe comorbidities *, n (%) [N=9947]		
Cardiovascular	11 (0.4)	58 (0.8)
Respiratory	15 (0.6)	106 (1.5)
Renal	139 (5.2)	36 (0.5)
Liver	5 (0.2)	39 (0.5)
Metastatic disease	11 (0.4)	47 (0.6)
Haematological malignancy	41 (1.5)	151 (2.1)
Immunocompromise	82 (3.1)	277 (3.8)
Prior hospital length of stay [N=10055]		
Mean (SD)	2.3 (5.2)	2.5 (6.5)
Median (IQR)	1 (0, 3)	1 (0, 3)
CPR within previous 24h, n (%) [N=10046]		<u> </u>
In the community	13 (0.2)	37 (0.6)
In hospital	16 (0.2)	56 (0.8)
Indicator of acute severity		
Mechanically ventilated within first 24h *, n (%) [N=9840]	2036 (77.3)	3795 (52.7)
APACHE II Score [N=9928]		
Mean (SD)	17.0 (5.5)	14.4 (5.0)
Median (IQR)	16 (13, 20)	14 (11, 17)
PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=9398]	14.4 (10.5, 20.0)	16.5 (11.6, 23.1)
PaO ₂ /FiO ₂ ratio †, n(%) [N=9398]		
≤ 13.3 kPa (≤ 100 mmHg)	1134 (43.9)	2312 (33.9)
> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg)	1164 (45.0)	3342 (49.1)
> 26.7 kPa (> 200 mmHg)	287 (11.1)	1159 (17.0)

^{*} Please see Definitions on page 39. Includes 175 patients requiring chronic renal replacement therapy for end stage renal disease prior to critical care; outcomes for these patients are similar. Indicators of acute severity are based on data from the first 24 hours of critical care. † Derived from the arterial blood gas with the lowest PaO₂ from the first 24 hours of critical care.

Critical care outcomes have been received for 10,118 (of 10,492) patients, of whom 4047 patients have died and 6071 have been discharged alive from critical care (Figures 12-14). Duration of critical care and receipt and duration of organ support in critical care are summarised in Table 9 and compared with an historic cohort of patients critically ill with viral pneumonia (non-COVID-19) admitted between 1 January 2017 and 31 December 2019. Receipt and duration of organ support are summarised graphically in Figure 15 and in Figure 16, respectively. Of the 6071 patients discharged from critical care, 613 (10.1%) were last reported to be still in an acute hospital setting and 283 (4.7%) died before being discharged from hospital (Figure 12).

Please note that Figure 14 is biased towards longer lengths of stay in critical care due to the time lag in notification of a patients' discharge or death, while Table 9 and Figures 15 and 16 are biased towards patients with shorter lengths of stay in critical care due to the ongoing nature of the UK epidemic. Figure 13 and Figure 14 assume that patients are still in critical care unless ICNARC has been notified otherwise, and Table 9 and Figures 15 and 16 include only those patients who have either died or been discharged from critical care.




Figure 12 Critical care and acute hospital outcomes among patients with at least 24h data received




Figure 13 Cumulative outcomes by date of start of critical care *

^{*} Please note that patients whose outcome data have not been received are assumed to remain in critical care as of 16 July 2020.




Figure 14 Survival and discharge among patients with at least 24h data received

Please note that due to the time lag in notification of patients' discharge or death, this figure is expected to be biased towards *longer* lengths of stay in critical care. Patients who are still in critical care are included only for the period in which they are known to have been in critical care, i.e. from their date of admission until 16 July 2020. Due to the ongoing nature of the UK epidemic, the total number of patients available for reporting becomes smaller at longer lengths of follow-up. Compared with the survival statistics presented in Tables 9, 13 and 14, this approach makes better use of all available data, including data about patients who are still in critical care.

Table 9 Outcome, duration of critical care and organ support *

Critical care outcomes among patients who have been discharged or died	Patients with COVID-19 and outcome reported (N=10118)	Patients with viral pneumonia (non-COVID-19), 2017-19 (N=5626)
Outcome at end of critical care, n (%)		
Discharged	6071 (60.0)	4423 (78.6)
Died	4047 (40.0)	1203 (21.4)
Duration of critical care		
Duration of critical care † (days), median (IQR)		
Survivors	12 (5, 27)	6 (3, 13)
Non-survivors	9 (5, 16)	6 (3, 13)
Organ support (Critical Care Minimum Dataset) *		
Receipt of organ support, at any point, n (%)		
Advanced respiratory support	7277 (72.2)	2721 (48.4)
Basic respiratory support	6799 (67.5)	4527 (80.5)
Advanced cardiovascular support	3009 (29.9)	1261 (22.4)
Basic cardiovascular support	9368 (92.9)	5219 (92.8)
Renal support	2673 (26.6)	957 (17.0)
Liver support	99 (1.0)	53 (0.9)
Neurological support	883 (8.8)	320 (5.7)
Combinations of advanced respiratory, advanced cardiovascular and renal support, n (%):		
Advanced respiratory support only	3173 (31.4)	1257 (22.3)
Advanced cardiovascular support only	45 (0.4)	79 (1.4)
Renal support only	120 (1.2)	116 (2.1)
Advanced respiratory and advanced cardiovascular support only	1545 (15.3)	640 (11.4)
Advanced respiratory and renal support only	1154 (11.4)	299 (5.3)
Advanced cardiovascular and renal support only	14 (0.1)	17 (0.3)
Advanced respiratory, advanced cardiovascular and renal support	1405 (13.9)	525 (9.3)
Duration of organ support (calendar days), median (IQR)		
Advanced respiratory support	13 (7, 23)	9 (4, 17)
Total (advanced + basic) respiratory support	11 (5, 21)	6 (3, 12)
Advanced cardiovascular support	3 (2, 6)	3 (2, 5)
Total (advanced + basic) cardiovascular support	11 (5, 21)	6 (3, 12)
Renal support	8 (3, 15)	6 (3, 12)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with confirmed COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. This does not apply to the comparison patients with viral pneumonia (non-COVID-19), 2017-19. * Please see Definitions on page 39. † Duration of critical care is from original admission to critical care until final unit outcome and includes any time spent outside critical care areas (e.g. prior to any readmissions).




Figure 15 Percentage of patients receiving organ support *

Please note that owing to the ongoing nature of the epidemic, the sample of patients with confirmed COVID-19 represented in this figure is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. patients who died or recovered quickly. * Please see Definitions on page 39.




Figure 16 Duration of organ support received *

This Figure presents median and interquartile range, in calendar days. Please note that owing to the ongoing nature of the epidemic, the sample of patients with confirmed COVID-19 represented in this figure is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. patients who died or recovered quickly. * Please see Definitions on page 39.

The median length of stay in hospital prior to the start of critical care, duration of critical care, and subsequent length of stay in hospital following discharge from critical care are summarised in Figure 17. Among patients who died in acute hospital following discharge from critical care, 21.8% were reported to have been discharged from critical care for palliative care. A total of 1324 inter-hospital critical care transfers for 1132 patients have been reported, as well as 255 readmissions for 244 patients (Figure 18).




Figure 17 Median lengths of stay among patients with hospital outcome data received

The numbers within each bar are the median and interquartile range, in days. Please note that owing to the ongoing nature of the epidemic, the sample of patients with confirmed COVID-19 represented in this figure is biased towards patients with *shorter* lengths of stay in acute hospital prior to discharge or death, i.e. patients who died or recovered more quickly.




Figure 18 Inter-hospital critical care transfers and readmissions

Critical care outcomes for patients critically ill with confirmed COVID-19 across major patient subgroups are summarised in Table 10 and compared with an historic cohort of patients critically ill with viral pneumonia (non-COVID-19) admitted between 1 January 2017 and 31 December 2019.

Table 10 Outcome by patient characteristics

Patient characteristic	Patients with Co outcome re (N=101	ported	Patients with viral pneumonia (non-COVID-19), 2017-19 (N=5782)
	Discharged alive from critical care	Died in critical care	Died in critical care
	n (%)	n (%)	(%)
Age at admission (years)			
16-39	690 (85.3)	119 (14.7)	(7.1)
40-49	1078 (78.5)	295 (21.5)	(12.1)
50-59	1855 (66.2)	947 (33.8)	(19.1)
60-69	1576 (52.9)	1405 (47.1)	(25.7)
70-79	743 (40.4)	1095 (59.6)	(31.2)
80+	124 (40.5)	182 (59.5)	(30.8)
Sex			
Female	1934 (64.6)	1061 (35.4)	(19.1)
Male	4133 (58.1)	2983 (41.9)	(23.3)
Ethnicity *			
White	3923 (60.9)	2517 (39.1)	(21.7)
Mixed	106 (59.9)	71 (40.1)	(14.0)
Asian	841 (56.0)	661 (44.0)	(19.4)
Black	553 (58.2)	397 (41.8)	(12.4)
Other	430 (65.4)	227 (34.6)	(18.6)
Index of Multiple Deprivation (IMD) quintile	e *		
1 (least deprived)	848 (62.0)	519 (38.0)	(22.3)
2	917 (60.8)	591 (39.2)	(22.6)
3	1103 (59.8)	741 (40.2)	(22.5)
4	1365 (59.8)	917 (40.2)	(20.1)
5 (most deprived)	1471 (60.9)	945 (39.1)	(20.3)
Body mass index			· · ·
<25	1475 (59.3)	1013 (40.7)	(23.1)
25-<30	1917 (57.7)	1408 (42.3)	(22.5)
30-<40	1906 (63.4)	1099 (36.6)	(18.9)
40+	492 (64.7)	268 (35.3)	(13.6)
Assistance required with daily activities			<u> </u>
No	5473 (61.1)	3484 (38.9)	(19.4)
Yes	528 (51.5)	498 (48.5)	(27.2)
Any very severe comorbidities *		·	
No	5598 (61.1)	3568 (38.9)	(18.8)
Yes	418 (49.7)	423 (50.3)	(32.8)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death (i.e. those who died or recovered quickly). This does not apply to the comparison patients with viral pneumonia (non-COVID-19), 2017-19. * Please see Definitions on page 39.

Critical care outcomes for patients of white ethnicities compared with patients of non-white ethnicities are summarised in Table 11.

Table 11 Outcome, duration of critical care and organ support by ethnicity *

Critical care unit outcomes among patients who have been discharged or died	Patients of white ethnicity (N=6440)	Patients of non-white ethnicity (N=3286)
Outcome at end of critical care, n (%)		
Alive	3923 (60.9)	1930 (58.7)
Dead	2517 (39.1)	1356 (41.3)
Duration of critical care		
Duration of critical care † (days), median (IQR)		
Survivors	11 (4, 25)	15 (6, 32)
Non-survivors	8 (4, 15)	10 (5, 17)
Organ support (Critical Care Minimum Dataset)*		
Receipt of organ support, at any point, n (%)		
Advanced respiratory support	4397 (68.5)	2594 (79.3)
Basic respiratory support	4461 (69.5)	2103 (64.3)
Advanced cardiovascular support	1816 (28.3)	1067 (32.6)
Basic cardiovascular support	5899 (91.9)	3109 (95.0)
Renal support	1511 (23.6)	1053 (32.3)
Liver support	42 (0.7)	48 (1.5)
Neurological support	549 (8.6)	302 (9.3)
Duration of organ support (calendar days), median (IQR)		
Advanced respiratory support	13 (7, 22)	14 (8, 24)
Total (advanced + basic) respiratory support	10 (5, 20)	13 (6, 24)
Advanced cardiovascular support	3 (2, 6)	3 (1, 6)
Total (advanced + basic) cardiovascular support	10 (5, 20)	13 (6, 24)
Renal support	8 (3, 14)	8 (3, 15)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39. Patients with ethnicity reported as 'not stated' excluded. † Duration of critical care is from original admission to critical care until final unit outcome and includes any time spent outside critical care areas (e.g. prior to any readmissions).

Figure 19 presents 30-day survival for patients critically ill with confirmed COVID-19 who received mechanical ventilation during the first 24 hours of critical care compared with patients who did not.

Critical care outcomes for patients critically ill with confirmed COVID-19 who received advanced respiratory support at any point during critical care and who received basic respiratory support only are summarised in Table 13. Critical care outcomes for patients critically ill with confirmed COVID-19 who received renal support at any point during critical care and who did not receive renal support are summarised in Table 14.




Figure 19 Survival and discharge by mechanical ventilation during the first 24 hours *

^{*} Please see Definitions on page 39. Patients who are still in critical care are included only for the period in which they are known to have been in critical care, i.e. from their date of start of critical care until 16 July 2020. The numbers of patients available for reporting (in brackets) are the number of patients who are known to have either died or been discharged on or before that time point plus the number of patients known to have been still in critical care beyond that time point. Due to the ongoing nature of the UK epidemic, the total number of patients available for reporting becomes smaller at longer lengths of follow-up. Compared with the survival statistics presented in Tables 9, 13 and 14, this approach makes better use of all available data, including data about patients who are still in critical care.

Table 12 Outcome by combinations of organ support *

Organ support received *	Patients with COVID-19 and outcome reported (N=10118)		Patients with viral pneumonia (non-COVID-19), 2017-19 (N=5782)
	Discharged alive from critical care	Died in critical care	Died in critical care
	n (%)	n (%)	(%)
Any respiratory support			
Basic only	2053 (80.3)	503 (19.7)	(11.2)
Advanced	3769 (51.8)	3508 (48.2)	(33.3)
Any renal support	1156 (42.9)	1537 (57.1)	(46.1)
Combinations of advanced respiratory, advanced cardiovascular and renal support:			
Advanced respiratory support only	2013 (63.4)	1160 (36.6)	(18.7)
Advanced respiratory and advanced cardiovascular support only	697 (45.1)	848 (54.9)	(40.2)
Advanced respiratory and renal support only	559 (48.4)	595 (51.6)	(38.8)
Advanced respiratory, advanced cardiovascular and renal support	500 (35.6)	905 (64.4)	(56.6)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39.

Table 13 Outcome, duration of critical care and organ support by receipt of respiratory support *

Critical care outcomes among patients who have been discharged or died	Patients receiving advanced respiratory support * (N=7277)	Patients receiving only basic respiratory support * (N=2556)
Outcome at end of critical care, n (%)		
Discharged	3769 (51.8)	2053 (80.3)
Died	3508 (48.2)	503 (19.7)
Duration of critical care		
Duration of critical care † (days), median (IQR)		
Survivors	22 (12, 36)	4 (2, 7)
Non-survivors	10 (5, 17)	4 (2, 7)
Organ support (Critical Care Minimum Dataset) *		
Receipt of organ support, at any point, n (%)		
Basic respiratory support	4235 (58.3)	2556 (100.0)
Advanced cardiovascular support	2950 (40.6)	42 (1.6)
Basic cardiovascular support	7015 (96.4)	2153 (84.2)
Renal support	2540 (35.0)	101 (4.0)
Liver support	95 (1.3)	3 (0.1)
Neurological support	856 (11.8)	23 (0.9)
Duration of organ support (calendar days), median (IQR)		
Total (advanced + basic) respiratory support	15 (8, 26)	4 (3, 7)
Advanced cardiovascular support	3 (2, 6)	2 (1, 4)
Total (advanced + basic) cardiovascular support	15 (8, 25)	4 (3, 7)
Renal support	8 (4, 15)	3 (2, 5)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39. Patients receiving no respiratory support excluded due to small numbers. † Duration of critical care is from original admission to critical care until final unit outcome and includes any time spent outside critical care areas (e.g. prior to any readmissions).

Table 14 Outcome, duration of critical care and organ support by receipt of renal support *

Critical care outcomes among patients who have been discharged or died	Patients receiving any renal support * (N=2673)	Patients not receiving any renal support * (N=7383)
Outcome at end of critical care, n (%)		
Discharged	1140 (42.6)	4886 (66.2)
Died	1533 (57.4)	2497 (33.8)
Duration of critical care		
Duration of critical care † (days), median (IQR)		
Survivors	31 (19, 44)	9 (4, 21)
Non-survivors	13 (7, 20)	7 (4, 13)
Organ support (Critical Care Minimum Dataset) *		
Receipt of organ support, at any point, n (%)		
Advanced respiratory support	2540 (95.0)	4718 (63.9)
Basic respiratory support	1451 (54.3)	5329 (72.2)
Advanced cardiovascular support	1414 (52.9)	1589 (21.5)
Basic cardiovascular support	2582 (96.6)	6760 (91.6)
Liver support	64 (2.4)	35 (0.5)
Neurological support	367 (13.8)	516 (7.0)
Duration of organ support (calendar days), median (IC	R)	
Advanced respiratory support	17 (10, 28)	11 (6, 20)
Total (advanced + basic) respiratory support	18 (11, 31)	9 (4, 17)
Advanced cardiovascular support	4 (2, 7)	3 (1, 5)
Total (advanced + basic) cardiovascular support	19 (10, 30)	9 (4, 18)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39. Includes 175 patients requiring chronic renal replacement therapy for end stage renal disease prior to critical care; outcomes for these patients are similar. † Duration of critical care is from original admission to critical care until final unit outcome and includes any time spent outside critical care areas (e.g. prior to any readmissions).

Critical care outcomes for patients critically ill with confirmed COVID-19 who received advanced respiratory support at any point during critical care and who received basic respiratory support only across major patient subgroups are summarised in Table 15. Critical care outcomes for patients critically ill with confirmed COVID-19 who received renal support at any point during critical care and who did not receive renal support across major patient subgroups are summarised in Table 16.

Table 15 Outcome by receipt of respiratory support * and patient characteristics

Patient	Patients receiving advanced respiratory support * tient (N=7277)		Patients receiving only basic respiratory support * (N=2556)	
characteristic	Discharged alive from critical care	Died in critical care	Discharged alive from critical care	Died in critical care
	n (%)	n (%)	n (%)	n (%)
Age at admission (year	ars)			
16-39	405 (78.5)	111 (21.5)	246 (97.2)	7 (2.8)
40-49	717 (72.9)	266 (27.1)	322 (92.3)	27 (7.7)
50-59	1221 (58.2)	877 (41.8)	587 (90.9)	59 (9.1)
60-69	1015 (44.5)	1266 (55.5)	495 (79.2)	130 (20.8)
70-79	381 (29.9)	892 (70.1)	323 (62.4)	195 (37.6)
80+	25 (21.4)	92 (78.6)	80 (48.5)	85 (51.5)
Sex				
Female	1138 (56.2)	888 (43.8)	694 (81.4)	159 (18.6)
Male	2628 (50.1)	2617 (49.9)	1358 (79.8)	344 (20.2)
Ethnicity *				
White	2284 (51.9)	2113 (48.1)	1477 (79.3)	386 (20.7)
Mixed	73 (52.9)	65 (47.1)	30 (83.3)	6 (16.7)
Asian	566 (49.0)	589 (51.0)	242 (79.9)	61 (20.1)
Black	401 (51.9)	371 (48.1)	132 (84.6)	24 (15.4)
Other	315 (59.5)	214 (40.5)	102 (90.3)	11 (9.7)
Index of Multiple Depr	rivation (IMD) quintile			
1 (least deprived)	477 (52.5)	432 (47.5)	327 (80.1)	81 (19.9)
2	548 (52.2)	501 (47.8)	338 (80.1)	84 (19.9)
3	715 (52.7)	641 (47.3)	347 (79.0)	92 (21.0)
4	873 (51.7)	814 (48.3)	434 (82.4)	93 (17.6)
5 (most deprived)	919 (53.4)	803 (46.6)	496 (78.4)	137 (21.6)
Body mass index				
<25	891 (50.8)	864 (49.2)	495 (78.6)	135 (21.4)
25-<30	1204 (49.0)	1252 (51.0)	642 (81.3)	148 (18.7)
30-<40	1278 (56.5)	985 (43.5)	565 (84.5)	104 (15.5)
40+	289 (55.6)	231 (44.4)	186 (83.8)	36 (16.2)
Assistance required w	rith daily activities			
No	3478 (52.5)	3146 (47.5)	1792 (85.1)	314 (14.9)
Yes	247 (44.1)	313 (55.9)	238 (57.5)	176 (42.5)
Any very severe como	orbidities *			
No	3562 (52.8)	3190 (47.2)	1828 (83.9)	350 (16.1)
Yes	172 (38.6)	274 (61.4)	208 (59.3)	143 (40.7)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39. Patients receiving no respiratory support excluded due to small numbers.

Table 16 Outcome by receipt of renal support * and patient characteristics

Patients receiving any renal support * Patient (N=2673)		Patients not receiving any renal support * (N=7383)		
characteristic	Discharged alive from critical care	Died in critical care	Discharged alive from critical care	Died in critical care
	n (%)	n (%)	n (%)	n (%)
Age at admission (year	ars)			
16-39	84 (64.1)	47 (35.9)	598 (89.3)	72 (10.7)
40-49	246 (67.4)	119 (32.6)	819 (82.6)	172 (17.4)
50-59	375 (47.5)	415 (52.5)	1469 (73.7)	525 (26.3)
60-69	310 (34.7)	584 (65.3)	1257 (60.5)	820 (39.5)
70-79	115 (25.2)	342 (74.8)	625 (45.5)	750 (54.5)
80+	7 (24.1)	22 (75.9)	116 (42.3)	158 (57.7)
Sex				
Female	273 (45.2)	331 (54.8)	1646 (69.5)	723 (30.5)
Male	867 (41.9)	1200 (58.1)	3236 (64.6)	1773 (35.4)
Ethnicity *				
White	642 (42.5)	869 (57.5)	3251 (66.4)	1642 (33.6)
Mixed	23 (52.3)	21 (47.7)	81 (61.8)	50 (38.2)
Asian	166 (38.8)	262 (61.2)	670 (63.1)	392 (36.9)
Black	189 (48.0)	205 (52.0)	361 (65.4)	191 (34.6)
Other	83 (44.4)	104 (55.6)	344 (73.8)	122 (26.2)
Index of Multiple Depr	rivation (IMD) quintile			
1 (least deprived)	147 (46.1)	172 (53.9)	686 (66.5)	345 (33.5)
2	150 (40.9)	217 (59.1)	760 (67.1)	372 (32.9)
3	253 (48.0)	274 (52.0)	838 (64.4)	463 (35.6)
4	252 (40.4)	372 (59.6)	1107 (67.3)	538 (32.7)
5 (most deprived)	284 (43.6)	367 (56.4)	1183 (67.3)	576 (32.7)
Body mass index				<u> </u>
<25	239 (40.2)	356 (59.8)	1227 (65.4)	649 (34.6)
25-<30	337 (37.9)	553 (62.1)	1565 (64.8)	851 (35.2)
30-<40	436 (48.3)	467 (51.7)	1457 (69.9)	627 (30.1)
40+	103 (50.5)	101 (49.5)	384 (69.7)	167 (30.3)
Assistance required w	vith daily activities			
No	1047 (42.9)	1396 (57.1)	4383 (67.9)	2074 (32.1)
Yes	82 (39.8)	124 (60.2)	445 (54.4)	373 (45.6)
Any very severe como	orbidities *			
No	1014 (42.5)	1374 (57.5)	4540 (67.6)	2180 (32.4)
Yes	118 (44.5)	147 (55.5)	300 (52.3)	274 (47.7)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. * Please see Definitions on page 39. Includes 175 patients requiring chronic renal replacement therapy for end stage renal disease prior to critical care; outcomes for these patients are similar.

Characteristics of patients critically ill with confirmed COVID-19 receiving critical care for 28 days or more are summarised in Table 17 and Table 18.

Table 17 Patient characteristics: demographics for patients receiving critical care for a total of 28 days or more

Demographics	Patients receiving critical care for 28 days or more (N=1869)
Age at admission (years) [N=1864]	
Mean (SD)	56.7 (10.9)
Median (IQR)	58 (50, 64)
Sex, n (%) [N=1866]	
Female	488 (26.2)
Male	1378 (73.8)
Currently or recently pregnant, n (% of females) [N=125]	
Currently pregnant	4 (3.2)
Recently pregnant (within 6 weeks)	6 (4.8)
Not known to be pregnant	115 (92.0)
Ethnicity *, n (%) [N=1811]	
White	1053 (58.1)
Mixed	46 (2.5)
Asian	340 (18.8)
Black	207 (11.4)
Other	165 (9.1)
Index of Multiple Deprivation (IMD) quintile *, n (%) [N=1781]	
1 (least deprived)	226 (12.7)
2	269 (15.1)
3	385 (21.6)
4	450 (25.3)
5 (most deprived)	451 (25.3)
Body mass index *, n (%) [N=1815]	
<18.5	9 (0.5)
18.5-<25	444 (24.5)
25-<30	607 (33.4)
30-<40	635 (35.0)
40+	120 (6.6)

^{*} Please see Definitions on page 39.

Table 18 Patient characteristics: medical history and indicators of acute severity for patients receiving critical care for a total of 28 days or more

Dependency prior to admission to acute hospital *, n (%) [N=1838] Able to live without assistance in daily activities 1736 (94.5) Some assistance with daily activities 101 (5.5) Total assistance with all daily activities 1 (0.1) Very severe comorbidities *, n (%) [N=1847] 2 Cardiovascular 4 (0.2) Respiratory 8 (0.4) Renal 22 (1.2) Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 2.1 (4.3) Mean (SD) 2.1 (4.3) Median (IQR) 1 (0.2) CPR within previous 24h, n (%) [N=1864] 1 In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 4.8 (2.6) Median (IQR) 14.8 (4.8) Median (IQR) 15.0 (11.0, 20.3) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) <	Medical history	Patients receiving critical care for 28 days or more (N=1869)
Some assistance with daily activities 101 (5.5) Total assistance with all daily activities 1 (0.1) Very severe comorbidities *, n (%) [N=1847] (0.2) Cardiovascular 4 (0.2) Respiratory 8 (0.4) Renal 22 (1.2) Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 3 Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 1 (0.2) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity 4 (0.0) Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 4 (4.8) Median (IQR) 14 (12, 18) PaO2/FiO2 ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO2/FiO2 ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) PaO3/FiO2 ratio †, n (%) [N=1807] 23 (40.0) \leq 13.3 kPa (\leq 100 mmHg) 723 (40.0)	Dependency prior to admission to acute hospital *, n (%) [N=1838]	
Total assistance with all daily activities 1 (0.1) Very severe comorbidities *, n (%) [N=1847] (0.2) Cardiovascular 4 (0.2) Respiratory 8 (0.4) Renal 22 (1.2) Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] Value Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 4 (0.0) In hospital 5 (0.1) Indicator of acute severity APACHE II Score [N=1851] 388 (75.4) Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 44 (1.2, 18) Median (IQR) 14 (12, 18) PaO2/FiO2 ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO2/FiO2 ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) > 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Able to live without assistance in daily activities	1736 (94.5)
Very severe comorbidities *, n (%) [N=1847] Cardiovascular 4 (0.2) Respiratory 8 (0.4) Renal 22 (1.2) Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 2.1 (4.3) Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 4 (0.0) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 14.8 (4.8) Median (IQR) 14 (12, 18) PaO2/FiO2 ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO2/FiO2 ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) PaO2/FiO2 ratio †, n (%) [N=1807] 723 (40.0) ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Some assistance with daily activities	101 (5.5)
$\begin{tabular}{ll} Cardiovascular & 4 & (0.2) \\ Respiratory & 8 & (0.4) \\ Renal & 22 & (1.2) \\ Liver & 2 & (0.1) \\ Metastatic disease & 6 & (0.3) \\ Haematological malignancy & 27 & (1.5) \\ Immunocompromise & 48 & (2.6) \\ \hline Prior hospital length of stay [N=1868] \\ Mean (SD) & 2.1 & (4.3) \\ Median (IQR) & 1 & (0,2) \\ \hline CPR within previous 24h, n (%) [N=1864] \\ In the community & 4 & (0.0) \\ In hospital & 5 & (0.1) \\ \hline \textbf{Indicator of acute severity} \\ \hline Mechanically ventilated within first 24h *, n (%) [N=1841] & 1388 & (75.4) \\ \hline APACHE II Score [N=1851] & 14.8 & (4.8) \\ Median (IQR) & 14 & (12, 18) \\ \hline PaO_2/FiO_2 ratio † (kPa), median (IQR) [N=1807] & 15.0 & (11.0, 20.3) \\ \hline PaO_2/FiO_2 ratio †, n (%) [N=1807] & 723 & (40.0) \\ > 13.3 & kPa & (\leq 100 \text{ mmHg}) & 723 & (40.0) \\ > 13.3 & and & \leq 26.7 & kPa & (> 100 \text{ and} \leq 200 \text{ mmHg}) & 905 & (50.1) \\ \hline \end{tabular}$	·	1 (0.1)
Respiratory Renal Liver Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy Immunocompromise 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] Mean (SD) Median (IQR) 2.1 (4.3) Median (IQR) 2.1 (4.3) CPR within previous 24h, n (%) [N=1864] In the community In hospital 15 (0.1) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] APACHE II Score [N=1851] Mean (SD) APACHE II Score [N=1851] APACHE II	• • • • •	
Renal 22 (1.2) Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] Mean (SD) 14.8 (4.8) Median (IQR) 14.8 (4.8) Median (IQR) 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Cardiovascular	4 (0.2)
Liver 2 (0.1) Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] Mean (SD) 14.8 (4.8) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Respiratory	, ,
Metastatic disease 6 (0.3) Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 2.1 (4.3) Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 4 (0.0) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity 3 Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 4 Mean (SD) 14.8 (4.8) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 5 ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Renal	22 (1.2)
Haematological malignancy 27 (1.5) Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 2.1 (4.3) Mean (SD) 2.1 (4.3) Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 4 (0.0) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity APACHE II Score [N=1851] Mean (SD) 14.8 (4.8) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 723 (40.0) ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Liver	2 (0.1)
Immunocompromise 48 (2.6) Prior hospital length of stay [N=1868] 2.1 (4.3) Mean (SD) 2.1 (0.2) CPR within previous 24h, n (%) [N=1864] 1 (0.2) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity 3.388 (75.4) Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 14.8 (4.8) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) ≥ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Metastatic disease	6 (0.3)
Prior hospital length of stay [N=1868] Mean (SD) Median (IQR) CPR within previous 24h, n (%) [N=1864] In the community In hospital In hospital Mechanically ventilated within first 24h *, n (%) [N=1841] APACHE II Score [N=1851] Mean (SD) Median (IQR) PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=1807] PaO_2 /FiO ₂ ratio †, n (%) [N=1807] ≤ 13.3 kPa (≤ 100 mmHg) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 2.1 (4.3) 2.1 (4.3) 2.1 (4.3) 2.1 (4.3) 4 (0.0) 1 1388 (75.4) 1388 (75.4) 1388 (75.4) 1489 (4.8) 15.0 (11.0, 20.3) 723 (40.0) 905 (50.1)	Haematological malignancy	27 (1.5)
$\begin{array}{lll} \mbox{Median (IQR)} & 2.1 \ (4.3) \\ \mbox{Median (IQR)} & 1 \ (0,2) \\ \mbox{CPR within previous 24h, n (%) [N=1864]} \\ \mbox{In the community} & 4 \ (0.0) \\ \mbox{In hospital} & 5 \ (0.1) \\ \mbox{Indicator of acute severity} \\ \mbox{Mechanically ventilated within first 24h *, n (%) [N=1841]} & 1388 \ (75.4) \\ \mbox{APACHE II Score [N=1851]} \\ \mbox{Mean (SD)} & 14.8 \ (4.8) \\ \mbox{Median (IQR)} & 14 \ (12, 18) \\ \mbox{PaO}_2/\text{FiO}_2 \ \text{ratio} \ \uparrow \ (\text{kPa}), \ \text{median (IQR) [N=1807]} & 15.0 \ (11.0, 20.3) \\ \mbox{PaO}_2/\text{FiO}_2 \ \text{ratio} \ \uparrow, n \ (\%) \ [N=1807] \\ \mbox{\le 13.3 kPa (\le 100 \ \text{mmHg})} & 723 \ (40.0) \\ \mbox{> 13.3 and } \le 26.7 \ \text{kPa} \ (> 100 \ \text{and} \le 200 \ \text{mmHg}) & 905 \ (50.1) \\ \end{tabular}$	Immunocompromise	48 (2.6)
Median (IQR) 1 (0, 2) CPR within previous 24h, n (%) [N=1864] 4 (0.0) In the community 4 (0.0) In hospital 5 (0.1) Indicator of acute severity 3 (0.1) Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 14.8 (4.8) Mean (SD) 14.8 (4.8) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 723 (40.0) ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	Prior hospital length of stay [N=1868]	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Mean (SD)	2.1 (4.3)
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Median (IQR)	1 (0, 2)
In hospital $5 (0.1)$ Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] $1388 (75.4)$ APACHE II Score [N=1851] $14.8 (4.8)$ Mean (SD) $14.8 (4.8)$ Median (IQR) $14 (12, 18)$ PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] $15.0 (11.0, 20.3)$ PaO₂/FiO₂ ratio †, n (%) [N=1807] $13.3 \text{ kPa} (≤ 100 \text{ mmHg})$ $723 (40.0)$ > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) $905 (50.1)$	CPR within previous 24h, n (%) [N=1864]	
Indicator of acute severity Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 14.8 (4.8) Mean (SD) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 15.0 (11.0, 20.3) ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	In the community	4 (0.0)
Mechanically ventilated within first 24h *, n (%) [N=1841] 1388 (75.4) APACHE II Score [N=1851] 14.8 (4.8) Mean (SD) 14 (12, 18) Median (IQR) 14 (12, 18) PaO₂/FiO₂ ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO₂/FiO₂ ratio †, n (%) [N=1807] 723 (40.0) ≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	In hospital	5 (0.1)
$\begin{array}{lll} & & & & \\ & \text{APACHE II Score [N=1851]} \\ & \text{Mean (SD)} & & 14.8 (4.8) \\ & \text{Median (IQR)} & & 14 (12, 18) \\ & \text{PaO}_2/\text{FiO}_2 \text{ ratio} \uparrow (\text{kPa}), \text{ median } (\text{IQR) [N=1807]} & 15.0 (11.0, 20.3) \\ & \text{PaO}_2/\text{FiO}_2 \text{ ratio} \uparrow, n (\%) [\text{N=1807]} \\ & \leq 13.3 \text{ kPa } (\leq 100 \text{ mmHg}) & 723 (40.0) \\ & > 13.3 \text{ and } \leq 26.7 \text{ kPa } (> 100 \text{ and } \leq 200 \text{ mmHg}) & 905 (50.1) \\ \end{array}$	Indicator of acute severity	
$\begin{array}{ll} \text{Mean (SD)} & 14.8 \ (4.8) \\ \text{Median (IQR)} & 14 \ (12, 18) \\ \hline \text{PaO}_2/\text{FiO}_2 \ \text{ratio} \ \dagger \ (\text{kPa}), \ \text{median (IQR)} \ [\text{N=1807}] & 15.0 \ (11.0, 20.3) \\ \hline \text{PaO}_2/\text{FiO}_2 \ \text{ratio} \ \dagger, \ \text{n (\%)} \ [\text{N=1807}] & \\ \leq 13.3 \ \text{kPa} \ (\leq 100 \ \text{mmHg}) & 723 \ (40.0) \\ > 13.3 \ \text{and} \ \leq 26.7 \ \text{kPa} \ (> 100 \ \text{and} \ \leq 200 \ \text{mmHg}) & 905 \ (50.1) \\ \end{array}$	Mechanically ventilated within first 24h *, n (%) [N=1841]	1388 (75.4)
Median (IQR) 14 (12, 18) PaO_2/FiO_2 ratio † (kPa), median (IQR) [N=1807] 15.0 (11.0, 20.3) PaO_2/FiO_2 ratio †, n (%) [N=1807]	APACHE II Score [N=1851]	
$\begin{array}{ll} \text{PaO}_2/\text{FiO}_2 \text{ ratio} \uparrow \text{ (kPa), median (IQR) [N=1807]} & 15.0 \text{ (}11.0, 20.3\text{)} \\ \text{PaO}_2/\text{FiO}_2 \text{ ratio} \uparrow, \text{ n (%) [N=1807]} \\ \leq 13.3 \text{ kPa (} \leq 100 \text{ mmHg)} & 723 \text{ (}40.0\text{)} \\ > 13.3 \text{ and } \leq 26.7 \text{ kPa (} > 100 \text{ and } \leq 200 \text{ mmHg)} & 905 \text{ (}50.1\text{)} \end{array}$	Mean (SD)	14.8 (4.8)
$PaO_2/FiO_2 \text{ ratio } \uparrow, \text{ n (\%) [N=1807]}$ $\leq 13.3 \text{ kPa (} \leq 100 \text{ mmHg)}$ 723 (40.0) > 13.3 and $\leq 26.7 \text{ kPa (} > 100 \text{ and } \leq 200 \text{ mmHg)}$ 905 (50.1)	Median (IQR)	14 (12, 18)
≤ 13.3 kPa (≤ 100 mmHg) 723 (40.0) > 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	PaO ₂ /FiO ₂ ratio † (kPa), median (IQR) [N=1807]	15.0 (11.0, 20.3)
> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg) 905 (50.1)	PaO ₂ /FiO ₂ ratio †, n (%) [N=1807]	
· · · · · · · · · · · · · · · · · · ·	≤ 13.3 kPa (≤ 100 mmHg)	723 (40.0)
> 26.7 kPa (> 200 mmHg) 179 (9.9)	> 13.3 and ≤ 26.7 kPa (> 100 and ≤ 200 mmHg)	905 (50.1)
	> 26.7 kPa (> 200 mmHg)	179 (9.9)

^{*} Please see Definitions on page 39. Indicators of acute severity are based on data from the first 24 hours of critical care. † Derived from the arterial blood gas with the lowest PaO₂ during the first 24 hours of critical care.

Critical care outcomes for patients critically ill with confirmed COVID-19 receiving critical care for 28 days or more are summarised in Table 19.

Table 19 Outcome, duration of critical care and organ support for patients receiving critical care for a total of 28 days or more

Critical care unit outcomes among patients who have been discharged or died	Patients receiving critical care for 28 days or more (N=1727)
Outcome at end of critical care, n (%)	
Alive	1472 (85.2)
Dead	255 (14.8)
Duration of critical care	
Duration of critical care † (days), median (IQR)	
Survivors	40 (33, 49)
Non-survivors	34 (30, 41)
Organ support (Critical Care Minimum Dataset)*	
Receipt of organ support, at any point, n (%)	
Advanced respiratory support	1698 (98.7)
Basic respiratory support	1445 (84.0)
Advanced cardiovascular support	781 (45.5)
Basic cardiovascular support	1707 (99.2)
Renal support	810 (47.2)
Liver support	44 (2.6)
Neurological support	314 (18.4)
Duration of organ support (calendar days), median (IQR)	
Advanced respiratory support	33 (27, 41)
Total (advanced + basic) respiratory support	37 (31, 46)
Advanced cardiovascular support	4 (2, 9)
Total (advanced + basic) cardiovascular support	36 (30, 45)
Renal support	16 (8, 25)

Please note that owing to the ongoing nature of the epidemic, the sample of patients with confirmed COVID-19 represented in this table is biased towards patients with *shorter* lengths of stay in critical care prior to discharge or death, i.e. those who died or recovered quickly. This does not apply to the comparison patients with viral pneumonia (non-COVID-19), 2017-19. * Please see Definitions on page 39. † Duration of critical care is from original admission to critical care until final unit outcome and includes any time spent outside critical care areas (e.g. prior to any readmissions).

Patient population:

- A multivariable Cox proportional hazards regression model was developed based solely on available data from patients critically ill with confirmed COVID-19 with a start of critical care between 1 March and 21 April 2020, locked on 4 June 2020.
- All patients were followed up for a minimum of 7 days, and outcomes were censored at 30 days following the start of critical care. Patients discharged alive from hospital within 30 days, and those ending critical care within 30 days with missing hospital outcome were assumed to survive to 30 days.
- Patients either with a duration of critical care of less than 24 hours or with no data recorded for any core physiology (temperature, systolic blood pressure, heart rate or respiratory rate) were excluded.

Prognostic factors:

- Prognostic factors were selected, a priori, based on established relationships with outcome for critically ill patients and on emerging information from the COVID-19 pandemic.
- Continuous prognostic factors were assessed for non-linearity using restricted cubic splines with up to five knots.
- Missing data were imputed using fully conditional specification (with models fitted in ten multiply imputed datasets and results combined).

Results:

- Of 6989 patients, 58 had a duration of critical care of less than 24 hours and 595 had no data recorded for any core physiology; a cohort of 6336 patients were included in the model.
- The results of the multivariable modelling are presented in Figures 20-22.

Explanation:

- The figures present the hazard ratio (solid lines or points) for values of each prognostic factor compared with a reference value (as indicated).
- A hazard ratio is a measure of how much more or less likely the event (death) is to occur.

For example, a patient aged 70 has a hazard ratio of approximately 2 compared with a patient aged 60; this means that they are twice as likely to die within 30 days of the start of critical care. In contrast, a patient aged 40 has a hazard ratio of approximately 0.5 compared with a patient aged 60; this means that they are half as likely to die within 30 days of the start of critical care. A hazard ratio of 1 means that the risk of death is the same.

 The hazard ratios indicate the association between each prognostic factor and the outcome adjusted for the effect of all the other variables in the model.

For example, the hazard ratio for dependency is adjusted for patients with dependency being older on average than those without dependency.

• The estimated hazard ratios are shown with 95% confidence intervals (as dashed lines or vertical spikes) indicating a range of possible values for the hazard ratio that will include the true value 19 times out of 20.

A manuscript reporting the full details of the modelling has been submitted for publication.




Figure 20 Hazard ratios and 95% confidence intervals from Cox proportional hazards regression model for death within 30 days following start of critical care: demographics and medical history

Please note that hazard ratios (HR) are reported relative to the median value for age (60 years) and the threshold for defining obesity for body mass index (30 kg/m²). Immunocompromised includes the conditions as defined on page 39 and also metastatic disease and haematological malignancy.




Figure 21 Hazard ratios and 95% confidence intervals from Cox proportional hazards regression model for death within 30 days following start of critical care: physiology (1)

Please note that hazard ratios (HR) are reported relative to the median value for each physiological parameter (as indicated on the y-axis) except for PaO₂/FiO₂ which is reported relative to the threshold for defining ARDS (26.7 kPa).




Figure 22 Hazard ratios and 95% confidence intervals from Cox proportional hazards regression model for death within 30 days following start of critical care: physiology (2)

Please note that hazard ratios (HR) are reported relative to the median value for each physiological parameter (as indicated on the y-axis).

Completeness of key variables is summarised in Table 20.

Table 20 Data completeness of key variables

Variable	N missing %
24h variables (N=10492)	
NHS number (used to combine transfers and readmissions)	213 (2.0)
Age	1 (0.0)
Sex	7 (0.1)
Currently or recently pregnant	3 (0.4) †
Ethnicity *	417 (4.0)
Index of Multiple Deprivation	721 (6.9)
BMI	574 (5.5)
Prior dependency *	175 (1.7)
Very severe comorbidities *	135 (1.3)
Prior hospital length of stay	6 (0.1)
CPR within previous 24h	22 (0.2)
Mechanical ventilation during the first 24h *	306 (2.9)
APACHE II Score	179 (1.7)
PaO2/FiO2 ratio	756 (7.2)
Outcome variables (N=10118)	
Length of stay in critical care	81 (0.8)
Advanced respiratory support *	42 (0.4)
Basic respiratory support *	43 (0.4)
Advanced cardiovascular support *	52 (0.5)
Basic cardiovascular support *	36 (0.4)
Renal support *	62 (0.6)
Liver support *	79 (0.8)
Neurological support *	75 (0.7)

 $^{^{\}star}$ Please see Definitions on page 39; † % of female patients aged 16-49 years

Patients are classified as either:

- Notification only received: ICNARC has received a notification of the patient's admission to critical care but has not received any patient data from the first 24 hours or beyond
- 24h data only received: ICNARC has received patient data relating to the first 24 hours in critical care but has not yet been notified of the patient's critical care outcome
- Outcome data received: ICNARC has received submission of data relating to the patient's <u>critical care</u> outcome (e.g. survival, length of stay, duration of organ support)
- Hospital outcome data received: Data have been updated with outcomes at ultimate discharge from hospital

Ethnicity is recorded using the ethnic category codes from the 2001 census and grouped as:

- White: White British; White Irish; White any other
- Mixed: Mixed white and black Caribbean; Mixed white and black African; Mixed white and Asian; Mixed any other
- Asian: Asian or Asian British Indian; Asian or Asian British Pakistani; Asian or Asian British – Bangladeshi; Asian or Asian British – any other
- Black: Black or black British Caribbean; Black or black British African; Black or black British – any other
- Other: Other ethnic group Chinese; Any other ethnic group
- · Not stated or not recorded

Index of Multiple Deprivation (IMD) is based on the patient's usual residential postcode (assigned at the level of Lower Layer Super Output Area) according to:

- English Index of Multiple Deprivation 2019 for postcodes in England
- Welsh Index of Multiple Deprivation 2019 for postcodes in Wales
- Northern Ireland Multiple Deprivation Measure 2017 for postcodes in Northern Ireland

Body mass index is calculated as the weight in kilograms divided by the height in metres squared. Weight and height values may have been measured or estimated.

Dependency prior to admission to acute hospital is assessed as the best description for the dependency of the patient in the two weeks prior to admission to acute hospital and prior to the onset of the acute illness, i.e. "usual" dependency. It is assessed according to the amount of personal assistance they receive with daily activities (bathing, dressing, going to the toilet, moving in/out of bed/chair, continence and eating).

Very severe comorbidities must have been evident within the six months prior to critical care and documented at or prior to critical care:

- Cardiovascular: symptoms at rest
- Respiratory: shortness of breath with light activity or home ventilation
- Renal: renal replacement therapy for end-stage renal disease
- Liver: biopsy-proven cirrhosis, portal hypertension or hepatic encephalopathy
- Metastatic disease: distant metastases
- Haematological malignancy: acute or chronic leukaemia, multiple myeloma or lymphoma
- Immunocompromise: chemotherapy, radiotherapy or daily high dose steroid treatment in previous six months, HIV/AIDS or congenital immune deficiency

Mechanical ventilation during the first 24 hours was identified by the recording of a ventilated respiratory rate, indicating that all or some of the breaths or a portion of the breaths (pressure support) were delivered by a mechanical device. This usually indicates invasive ventilation; BPAP (bilevel positive airway pressure) would meet this definition but CPAP (continuous positive airway pressure) does not.

Organ support is recorded as the number of calendar days (00:00-23:59) on which the support was received at any time, defined as:

- Advanced respiratory: invasive ventilation, BPAP via trans-laryngeal tube or tracheostomy, CPAP via trans-laryngeal tube, extracorporeal respiratory support
- Basic respiratory: >50% oxygen by face mask, close observation due to potential for acute deterioration, physiotherapy/suction to clear secretions at least two-hourly, recently extubated after a period of mechanical ventilation, mask/hood CPAP/BPAP, non-invasive ventilation, CPAP via a tracheostomy, intubated to protect airway
- Advanced cardiovascular: multiple IV/rhythm controlling drugs (at least one vasoactive), continuous observation of cardiac output, intra-aortic balloon pump, temporary cardiac pacemaker
- Basic cardiovascular: central venous catheter, arterial line, single IV vasoactive/ rhythm controlling drug
- Renal: acute renal replacement therapy, renal replacement therapy for chronic renal failure where other organ support is received
- Liver: management of coagulopathy and/or portal hypertension for acute on chronic hepatocellular failure or primary acute hepatocellular failure
- Neurological: central nervous system depression sufficient to prejudice airway, invasive neurological monitoring, continuous IV medication to control seizures, therapeutic hypothermia

Acknowledgement

Please acknowledge the source of these data in all future presentations (oral and/or written), as follows:

"These data derive from the ICNARC Case Mix Programme Database. The Case Mix Programme is the national clinical audit of patient outcomes from adult critical care coordinated by the Intensive Care National Audit & Research Centre (ICNARC). For more information on the representativeness and quality of these data, please contact ICNARC."